Glucophage · Metformin HCl · Metformin XR
Metformin (dimethylbiguanide) is the most widely prescribed oral medication for type 2 diabetes worldwide, with over 150 million prescriptions annually. First approved in Europe in 1957 and by the FDA in 1995, it remains the first-line pharmacotherapy for type 2 diabetes per ADA guidelines. Metformin is derived from the French lilac (Galega officinalis), a plant used in medieval European folk medicine for diabetes symptoms.
Take with meals to reduce GI side effects. Start low (500mg with dinner) and titrate up over 2-4 weeks. Extended-release (ER) formulation significantly reduces GI side effects. Take evening dose for maximum overnight glucose suppression.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
Metformin's primary action is inhibition of mitochondrial Complex I in hepatocytes, which increases the AMP:ATP ratio and activates AMPK. Activated AMPK suppresses hepatic gluconeogenesis (the liver's production of new glucose), which accounts for metformin's main glucose-lowering effect. Unlike sulfonylureas or insulin, metformin does not cause hypoglycemia in non-diabetics because it does not stimulate insulin secretion.
Additional metabolic effects include enhanced peripheral glucose uptake in skeletal muscle (via GLUT4 translocation), reduced intestinal glucose absorption, improved insulin receptor sensitivity, and modulation of the gut microbiome (increased Akkermansia muciniphila, improved short-chain fatty acid production). GLP-1 secretion is also enhanced, contributing to improved glucose-dependent insulin release.
Anti-aging mechanisms are multifaceted: AMPK activation inhibits mTOR signaling (the same pathway targeted by rapamycin), promoting autophagy and cellular housekeeping. Metformin reduces systemic inflammation (lower CRP, IL-6, TNF-alpha), decreases oxidative stress, improves mitochondrial function, and activates cellular stress response pathways (hormesis). These effects collectively mimic aspects of caloric restriction - the most robust intervention for extending lifespan in animal models.
Weeks 1-2: GI adjustment period. Early blood glucose improvements.
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
Evidence boundary from the checked abstract: The lifestyle intervention was more effective than metformin.
The lifestyle intervention was more effective than metformin.
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Evidence scope. This entry supports only the exact statement quoted from the live abstract; it does not independently verify OnePin's displayed dose, route, frequency, formulation, population, or broader mechanism.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Dose/route: 500mg; Oral; 1-2x daily with meals. No checked live PubMed abstract verified this exact displayed dose, route, and frequency for the same molecule/formulation and relevant population.
Primary safety claim: GI effects: nausea, diarrhea, abdominal cramping, metallic taste (20-30%, improves with time and ER formulation). No checked live PubMed abstract directly verified this source-JSON safety claim at the displayed formulation, route, and regimen.
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
Plasma elimination half-life
(immediate-release), ~7 hours (extended-release)
>95% eliminated in urine within 24 hours
Oral (not affected by food, though food delays absorption and reduces GI effects)
Glucose-lowering effects: 8-12 hours per dose. AMPK activation and metabolic effects require continuous daily dosing.
Renal (excreted unchanged in urine via tubular secretion and glomerular filtration). No hepatic metabolism. Dose adjustment required if eGFR <45 mL/min. Contraindicated if eGFR <30 mL/min.
Storage. Store at room temperature (20-25C). Protect from light and moisture. Extended-release tablets should not be crushed or split. Shelf life typically 2-3 years. No special storage requirements.
FDA-approved prescription medication for type 2 diabetes mellitus (Glucophage, generic). Off-label use for prediabetes, PCOS, weight management, and longevity. Prescription required in the US. One of the most affordable prescription medications available. WHO Essential Medicine.
Put it to work
Open Metformin straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Metformin in the app →Go deeper
The complete Metformin walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.